In Plasmodium falciparum, resistance to folate inhibitors like pyrimethamine is mediated by
point mutations in the target gene dihydrofolate reductase (dhfr). The resistance to …

We have expressed dhfr alleles of Plasmodium falciparum in the budding yeast,
Saccharomyces cerevisiae, and used this yeast model to identify single amino acid …

Differential resistance of Plasmodium falciparum to the antimalarial drugs pyrimethamine
and cycloguanil (the active metabolite of proguanil) results from specific mutations in …

Two new dihydrofolate reductase (DHFR) mutations were recently discovered in
Plasmodium falciparum samples from an area of Bolivia with high rates of in vivo resistance …

Plasmodium falciparum, the protozoan that causes the most lethal form of human malaria,
has been controlled principally by two safe, affordable drugs, chloroquine and sulfadoxine …

The nucleotide sequence of the dihydrofolate reductase-thymidylate synthase (DHFR-TS)
gene in pyrimethamine-resistant (Pyr R) mutants of Plasmodium falciparum selected in vitro …

Single and multiple mutations at residues 16, 51, 59, 108, and 164 of Plasmodium
falciparum dihydrofolate reductase (pfDHFR) have been linked to antifolate resistance in …

Inhibitors of dihydrofolate reductase (DHFR) have been a mainstay of chemotherapy of
falciparum malaria for> 50 years. Unfortunately, point mutations in DHFR are the major …

Drugs that target the folate‐synthesis pathway have a long history of effectiveness against a
variety of pathogens. As antimalarials, the antifolates were safe and well tolerated, but …

Natural mutations of Plasmodium falciparum dihydrofolate reductase (Pf DHFR) at A16V and
S108T specifically confer resistance to cycloguanil (CYC) but not to pyrimethamine (PYR). In …